Genentech Reorganization Signals Shift To New Model Under Roche
Executive Summary
A management shakeup at Genentech following Roche's takeover in March clearly signals a transformation for the biotech. Among the key leadership changes is the appointment of Roche commercial pharma head Pascal Soriot to CEO of Genentech
You may also be interested in...
Orphans Should Live Alone
For larger organizations with interests in rare diseases, Bionest Partners believes it is necessary to maintain a separation from the rest of the company in order to keep the culture needed for successful product commercialization. Easier said than done.
Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski
What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.
Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski
What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.